Deals: Page
-
Two San Diego biotechs merge to create new oncology-focused company
Oncternal Therapeutics and Tokalas aim to advance two early-stage cancer drugs.
By Nicole Gray • June 2, 2016 -
Report: Investors concerned Teva overpaid for Allergan generics unit
Teva is currently working to win U.S. approval for its $41 billion deal, which cleared regulatory review in Europe earlier this year.
By Nicole Gray • June 2, 2016 -
Intercept shares climb on FDA approval of liver drug
Ocaliva, or obeticholic acid, is the first new treatment for primary biliary cholangitis to reach the market in nearly 20 years.
By Ned Pagliarulo • May 31, 2016 -
Wellcome Trust scores with startup investment in diagnostic company
Blue Earth Diagnostics, which is owned by the investment arm of Wellcome Trust, received FDA approval for a cancer diagnostic last Friday.
By Nicole Gray • May 31, 2016 -
Jazz Pharma snaps up leukemia drug with $1.5 billion deal for Celator
The $30.25 price per share is roughly double Celator's closing price last Friday.
By Ned Pagliarulo • May 31, 2016 -
Contract researcher BioClinica reportedly weighing sale
The CRO market has been consolidating with major mergers announced or rumored over the past year.
By Nicole Gray • May 27, 2016 -
Fate of Ionis drug in doubt after GSK decides against Phase 3 study
The FDA had placed a clinical hold on the rare disease drug in April.
By Nicole Gray • May 27, 2016 -
Novartis moves toward sale of $14 billion stake in Roche
Challenges at Novartis' eye-care unit Alcon, along with slow sales for Entresto, have put pressure on the company.
By Nicole Gray • May 26, 2016 -
Courtesy of Sanofi
Sanofi goes after Medivation's board as takeover battle heats up
The current board would be replaced with eight directors hand-picked by Sanofi if the move is successful.
By Randy Lilleston • May 25, 2016 -
Arbor Pharma buys XenoPort for $467 million
Known for its restless leg syndrome treatment, XenoPort has fallen on hard times in the past year.
By Nicole Gray • May 24, 2016 -
Janssen ponies up $740 million for another MacroGenics cancer drug
Under the terms of the deal, Janssen will pay MacroGenics $75 million up front, with $665 million in potential milestone payments.
By Nicole Gray • May 19, 2016 -
Celgene expands partnership with Agios into immuno-oncology
Agios lands $200 million upfront, with the potential for much more in clinical and regulatory milestones.
By Nicole Gray • May 18, 2016 -
Editas forges $5 million CRISPR research deal with Cystic Fibrosis Foundation
While Editas has no approved drugs yet, the promise and hope surrounding gene-editing has spurred several development deals.
By Nicole Gray • May 17, 2016 -
With generics deal pending, Teva's Europe portfolio attracts buyers
Novartis and Mylan are both reportedly interested in acquiring Teva's businesses in the U.K., Ireland, and Iceland.
By Ned Pagliarulo • May 16, 2016 -
Pfizer adds eczema drug in $5.2 billion deal for Anacor
Anacor's main drug candidate, crisaborole, is currently under FDA review for treatment of eczema.
By Ned Pagliarulo • May 16, 2016 -
Baxter reportedly top suitor for Indian injectables maker
But the Chinese conglomerate Fosun Group has also made an offer, according to The Economic Times.
By Ned Pagliarulo • May 12, 2016 -
Daiichi snaps up Japanese rights to CVD stem-cell therapy
U.K.-based Cell Therapy will receive £12.5 million upfront from the Japanese company for its Heartcel product.
By Nicole Gray • May 11, 2016 -
Pfizer planning first triple-drug immuno-oncology study
Expected to begin sometime next year, the early-stage trial will combine the checkpoint inhibitor avelumab with two other drugs.
By Nicole Gray • May 11, 2016 -
Medicines Co. sells off cardiovascular drugs to Italy's Chiesi
The deal could be worth up to $792 million if all milestones are hit.
By Ned Pagliarulo • May 9, 2016 -
Lower sales of generic drugs weigh on Teva's first-quarter revenue
Still pending is a $40 billion acquisition of Allergan's generics business, which the Israel-based drugmaker expects to close in June.
By Ned Pagliarulo • May 9, 2016 -
As Big Pharma circles, Medivation makes case for independence
Sanofi has threatened to take its $9.3 billion takeover directly to shareholders if Medivation continues to rebuff negotiations.
By Ned Pagliarulo • May 6, 2016 -
Pfizer bets on Wave with drug development deal
The partnership could be worth up to $911 million if all milestones are hit.
By Nicole Gray • May 6, 2016 -
AMRI cuts $358M deal for Euticals
The deal will give AMRI a significant API portfolio in Europe.
By Randy Lilleston • May 5, 2016 -
Report: Pfizer considering takeover offer for sought-after Medivation
Medivation's board last week rejected a $9.3 billion bid from Sanofi, calling it a "substantially inadequate proposal."
By Ned Pagliarulo • May 4, 2016 -
IMS, Quintiles to merge in $9B deal
The all-stock deal unites two major providers of pharma support services.
By Randy Lilleston • May 3, 2016
Previous
